Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models-Reference-Cited by-同舟云学术

Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models

Published:2016-12-29 Issue:3 Volume:241 Page:362-374
ISSN:0022-3417
Container-title:The Journal of Pathology
language:en
Short-container-title:J. Pathol.

Author:

Bridgeman Victoria L¹,Vermeulen Peter B¹²,Foo Shane¹,Bilecz Agnes³,Daley Frances⁴,Kostaras Eleftherios¹,Nathan Mark R¹,Wan Elaine¹⁵,Frentzas Sophia¹⁵,Schweiger Thomas⁶,Hegedus Balazs⁷⁸,Hoetzenecker Konrad⁶,Renyi-Vamos Ferenc⁹,Kuczynski Elizabeth A¹⁰,Vasudev Naveen S¹⁵¹¹,Larkin James⁵,Gore Martin⁵,Dvorak Harold F¹²,Paku Sandor¹³¹⁴,Kerbel Robert S¹⁰¹⁵,Dome Balazs⁶⁹¹⁶¹⁷,Reynolds Andrew R¹

Affiliation:

1. Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre; The Institute of Cancer Research; London UK

2. Translational Cancer Research Unit (TCRU); GZA Hospitals St Augustinus; Antwerp Belgium

3. 2nd Institute of Pathology; Semmelweis University; Budapest Hungary

4. Breast Cancer Now Histopathology Core Facility, The Royal Marsden; London UK

5. The Royal Marsden; London UK

6. Department of Thoracic Surgery; Medical University of Vienna; Vienna Austria

7. Department of Thoracic Surgery, Ruhrlandklinik Essen; University Hospital of University Duisburg-Essen; Germany

8. MTA-SE Molecular Oncology Research Group; Hungarian Academy of Sciences; Budapest Hungary

9. Department of Thoracic Surgery; Semmelweis University-National Institute of Oncology; Budapest Hungary

10. Department of Medical Biophysics; University of Toronto; Toronto Canada

11. Cancer Research UK Centre, Leeds Institute of Cancer and Pathology; St James's University Hospital; Leeds UK

12. Beth Israel Deaconess Medical Center; Boston MA USA

13. 1st Department of Pathology and Experimental Cancer Research; Semmelweis University; Budapest Hungary

14. Tumour Progression Research Group; Hungarian Academy of Sciences-Semmelweis University; Budapest Hungary

15. Biological Sciences Platform, Sunnybrook Research Institute; Toronto Canada

16. National Koranyi Institute of Pulmonology; Budapest Hungary

17. Department of Biomedical Imaging and Image-guided Therapy; Medical University of Vienna; Austria

Funder

Breakthrough Breast Cancer

NHS

Hungarian Scientific Research Fund

Semmelweis University Start-Up grant

ÖNB Jubiläumsfondsprojekt

Vienna Fund for Innovative Interdisciplinary Cancer Research

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Reference46 articles.

1. Modes of resistance to anti-angiogenic therapy;Bergers;Nat Rev,2008

2. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis;Ebos;Nat Rev Clin Oncol,2011

3. Molecular mechanisms and clinical applications of angiogenesis;Carmeliet;Nature,2011

4. Controlling escape from angiogenesis inhibitors;Sennino;Nat Rev,2012

5. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions;Vasudev;Angiogenesis,2014

Cited by 161 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Inhibition of Vessel Co-Option as an Emerging Strategy for Cancer Therapy;International Journal of Molecular Sciences;2024-01-11

2. Vascular co-option in resistance to anti-angiogenic therapy;Frontiers in Oncology;2023-12-11

3. PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors;Clinical Cancer Research;2023-09-21

4. Targeting endothelial permeability in the EPR effect;Journal of Controlled Release;2023-09

5. Therapeutic advances targeting tumor angiogenesis in pancreatic cancer: Current dilemmas and future directions;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-09